Navigation Links
Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Date:2/3/2016

SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference in New York City.

The live presentation takes place on Wednesday, February 10 at 11:55am ET (8:55am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and valbenazine, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
2. Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
3. Neurocrine Biosciences to Present at Credit Suisses 24th Annual Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results
5. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
6. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
7. Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors
8. Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
9. Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference
10. Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study
11. Neurocrine Biosciences Reports Second Quarter 2015 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... Calif. (PRWEB) , ... August 27, 2020 , ... ... the conclusion of its fundraising initiative for Feeding San Diego with a ... What: The GHT Companies presents the final check of $5,000.00+ representing an overall donation ...
(Date:8/26/2020)... (PRWEB) , ... August 26, 2020 , ... AseptiScope, a ... Infection Control Company of the Year by MedTech Outlook. , “AseptiScope is ... “For the first time, clinicians who wear gloves on their hands, goggles on their ...
(Date:8/26/2020)... ... 26, 2020 , ... Unscrupulous sellers across the country are ... purification technologies, including GreenTech Environmental’s proprietary methods, have been used successfully to curb ... has published results of singular and scientific testing against the coronavirus. , As ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... August 31, 2020 , ... ... 1,400 N95 face masks to medical first responders across the United States. Since ... donations of personal protective equipment (PPE) medical centers , hospitals , ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado ... through high-quality, career-relevant, and affordable online education – is proud to announce its ... Among the first of its kind in the nation, the 60-credit hour program ...
(Date:8/31/2020)... Hawaii (PRWEB) , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with ... people on the planet are in a state of panic, experiencing deep anxiety, immense stress, ... Right now, a solution is timely when most people on the planet are experiencing a ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, LLC, ... with advanced heart failure, today announced that the company has been awarded a ... from the National Heart, Lung, and Blood Institute of the National Institutes of ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... to help treat patients with respiratory conditions, including COVID-19, while reducing the need ... oxygen, but it captures exhaled gas and scrubs it free of carbon dioxide ...
Breaking Medicine News(10 mins):